Suggested Topics within your search.
Suggested Topics within your search.
- Cancer 1
- Gynecology 1
- Obstetrics 1
- Oncology 1
- Pediatric 1
- Pediatric Hematology 1
- Pediatric hematology 1
- methods 1
-
2041
-
2042
-
2043
-
2044
Increased PD-1 expression in livers associated with PD-1-antibody-induced hepatotoxicity
Published 2025-01-01Get full text
Article -
2045
-
2046
Efficacy and safety of immune checkpoint inhibitors in elderly patients with advanced non-small cell lung cancer: a systematic review and meta-analysisResearch in context
Published 2025-03-01“…In real-world studies, the pooled median OS of ICIs were 11.8 months (95% CI: 11.2–12.4); Eastern Cooperative Oncology Group (EOCG) score, histological type, PD-L1 status, with immune-related adverse events (irAEs), and treatment mode were predictive for OS; rates of irAEs and discontinuation were numerically higher for combination therapy vs. monotherapy. …”
Get full text
Article -
2047
-
2048
-
2049
-
2050
-
2051
Cancer cells avoid ferroptosis induced by immune cells via fatty acid binding proteins
Published 2025-02-01Get full text
Article -
2052
Primary Synovial Sarcoma of Kidney: A Rare Differential Diagnosis of Renomegaly
Published 2014-01-01Get full text
Article -
2053
-
2054
-
2055
Radiation dose and fraction in immunotherapy: one-size regimen does not fit all settings, so how does one choose?
Published 2021-04-01“…Radiation oncologists and immunologists convened a virtual consensus discussion to identify current deficiencies, challenges, pitfalls and critical gaps when combining radiotherapy with immunotherapy and making recommendations to the field and advise National Cancer Institute on new directions and initiatives that will help further development of these two fields.This commentary aims to raise the awareness of this complexity so that the need to study radiation dose, fractionation, type and volume is understood and valued by the immuno-oncology research community. Divergence of approaches and findings between preclinical studies and clinical trials highlights the need for evaluating the design of future clinical studies with particular emphasis on radiation dose and fractionation, immune biomarkers and selecting appropriate end points for combination radiation/immune modulator trials, recognizing that direct effect on the tumor and potential abscopal effect may well be different. …”
Get full text
Article -
2056
Venetoclax plus low-intensity chemotherapy for adults with acute lymphoblastic leukemia
Published 2025-02-01Get full text
Article -
2057
-
2058
Immune microenvironment spatial landscapes of tertiary lymphoid structures in gastric cancer
Published 2025-02-01Get full text
Article -
2059
-
2060